Clinical trials: Risperidone, completed
Schizophrenia, Schizoaffective Disorder
Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone
The purpose of the study is to evaluate the characteristics, clinical responses, and safety issues of patients receiving long-term treatment of Risperidone long-acting injectable.
- Trial name
- NCT00644852
- Testing
- Retrospective chart review study
- Volunteers
- 342 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Schizophrenia
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone, In Schizophrenic Patients Previously…
- Trial name
- NCT00722176
- Testing
- BL-1020, BL-1020 10-30 mg, risperidone
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
This study evaluates PERSERIS at a higher dose than what has been administered in previous clinical trials. Subjects with stable schizophrenia on a dose of 5-6 mg oral risperidone will be switched to PERSERIS at the higher dose…
- Trial name
- NCT03978832
- Testing
- PERSERIS, Risperidone
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Indivior Inc.
Anxiety Disorders
Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.
The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment.
- Trial name
- NCT00086112
- Testing
- risperidone oral tablets
- Volunteers
- 301 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
This twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
- Trial name
- NCT00179062
- Testing
- olanzapine versus risperidone
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Vanderbilt University
Schizophrenia
Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility
This is an eight-week open-label randomized parallel group clinical trial focusing on the comparison of risperidone alone with risperidone plus valproate among hospitalized adult patients diagnosed with schizophrenia who also…
- Trial name
- NCT00308360
- Testing
- Risperidone, divalproex
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
The purpose of this study is to assess the safety, tolerability and PK profile of a single dose of 60mg RBO-7000 in stable subjects with schizophrenia who are on medication other than risperidone.
- Trial name
- NCT02765555
- Testing
- RBP-7000
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indivior Inc.
Schizophrenia
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia
The aim of this study to evaluate the efficacy and safety of pentoxifylline, the novel phosphodiesterase inhibitor, as an adjunctive to risperidone in alleviating the negative symptoms of schizophrenia.
- Trial name
- NCT04094207
- Testing
- Pentoxifylline
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sadat City University
Schizophrenia
Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies
The overarching goal is to identify imaging markers that will predict treatment response, and to confirm or validate these biomarkers using anatomical studies of postmortem tissue.
- Trial name
- NCT00937716
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Bipolar Disorder
A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder
The purpose of this study is to determine the safety and effectiveness of a long-acting injectable formulation of risperidone in stable bipolar patients randomly switched from their current add-on oral antipsychotic (olanzapine…
- Trial name
- NCT00246246
- Testing
- risperidone
- Volunteers
- 48 people
- Sponsor
- Janssen-Ortho Inc., Canada
Conduct Disorder, Oppositional Defiant Disorder
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild…
- Conditions
- Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder
- Trial name
- NCT00250354
- Testing
- Risperidone oral solution
- Volunteers
- 110 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Healthy
Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions
The objective of this study was to compare the rate and extent of absorption of risperidone 1 mg tablets (test) versus Risperdal® (reference) administered as a 1 x 1 mg tablet under fasting conditions.
- Trial name
- NCT00830349
- Testing
- Risperidone
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Schizophrenia
Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.
The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when…
- Trial name
- NCT00828958
- Testing
- Risperidone long-acting injectable
- Volunteers
- 53 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
The purpose of the study is to assess the safety and effectiveness of risperidone (an antipsychotic medication) in adolescents with schizophrenia over 6 months of treatment.
- Trial name
- NCT00246285
- Testing
- risperidone
- Volunteers
- 381 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Volunteer
A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers
This single-center, randomized, double-blind, two-period crossover study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of the combination of multiple doses of RO5285119 with a single dose of…
- Trial name
- NCT01708616
- Testing
- RO5285119, risperidone
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Schizophrenia
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and…
- Trial name
- NCT02002832
- Testing
- Lurasidone tablets, Risperidone tablets
- Where
- 15 sites in China
- Volunteers
- 388 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia
A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
This is a Phase 1, open-label study to evaluate the safety and pharmacokinetics (PK) of three doses of risperidone-SABER, administered with a needle and syringe or via the DosePro Needle-Free Delivery System in patients with…
- Trial name
- NCT01592110
- Testing
- risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Zogenix, Inc.
Psychosis, Food-drug Interaction
KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution
Risperidone is widely used in the treatment of schizophrenia, bipolar disorder, and aggression associated with moderate or severe Alzheimer's dementia.
- Trial name
- KF2022#3 (NCT06218979)
- Testing
- Risperidone oral solution
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Cocaine-Related Disorders
Risperidone Treatment in Dually-Diagnosed Individuals - 2
The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
- Trial name
- NCT00000267
- Testing
- Risperidone
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia, Schizoaffective Disorders
An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
The purpose of this study is to evaluate the efficacy and safety of long-acting risperidone microspheres (small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various…
- Trial name
- NCT00526877
- Testing
- Risperidone
- Where
- Taiwan
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Taiwan Ltd